OOSTERHOUT, Netherlands,
Oct. 13 /PRNewswire-FirstCall/ --
Luminex Corporation (Nasdaq: LMNX), today announced that it will
host Planet xMAP Europe 2010, its
annual European multiplexing technology symposium, October 20-21, 2010, at The Hofburg in
Vienna, Austria. The event will
feature scientific sessions, workshops, discussion groups,
exhibitions and networking events with scientists and researchers
from around the world who are performing groundbreaking work in
clinical diagnostics and life science research using Luminex's
xMAP® multiplexing technology platform.
(Logo:
http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
(Logo:
http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)
"Planet xMAP Europe is an
excellent opportunity for scientists to gather and exchange ideas
on how xMAP multiplexing technology is revolutionizing their
laboratories and research," said Paul C. Ladestein, General Manager
European Operations for Luminex. "We look forward to welcoming
these leading scientists to our exciting new venue at The Hofburg
in Vienna."
Planet xMAP Europe 2010 will
feature two days of presentations with six focused session
options.
Day One of Planet xMAP Europe 2010, Wednesday, 20 October, will focus
on Pathogen Detection, Immunology-Monitoring and HLA-Human
Genetics.
The morning session will include the following
presentations:
- Professor Sabine Bahn, MD, PhD,
MRCPsych, of the Cambridge Centre for Neuropsychiatric Research
Institute of Biotechnology, University of
Cambridge, UK, "Disease Biomarkers in First-onset
Schizophrenia"
- Professor Jean Louis Merlin,
PharmD, PhD, of Tumor Biology Unit, Nancy University Centre Alexis
Vautrin, Vandoeuvre-les-Nancy, France, "Phosphoprotein array for
characterization of Human Tyrosine kinase receptors downstream
signaling functionality as response predictive marker to targeted
therapy in translational oncology research programs"
- Professor Alex van Belkum,
Department of Medical Microbiology and Infectious Diseases Erasmus
MC, Rotterdam, The Netherlands,
"Multi-parameter assessment of the humoral response to colonisation
and infection with opportunistic microbial pathogens from the human
Nasopharyngeal cavity"
- Professor Jonas Blomberg,
Section of Virology, Department of Medical Sciences, Uppsala University, Sweden, "More for less; multiplex broadly
targeted nucleic acid and serology analyses from the same clinical
sample"
- Tim Dehne, Vice President of
Systems Research and Development, Luminex Corporation, "MAGPIX: The
Next Dimension in Multiplexing"
The afternoon session will feature three separate tracks focused
on Pathogen Detection, Immunology-Monitoring, and Human
Genetics.
Day Two of Planet xMAP Europe 2010, Thursday, 21 October, will focus
on Protein and Genomic Research, and xTAG RVP Fast.
The morning session will include the following
presentations:
- Carlo M. Croce, MD, Department
of Molecular Virology, Immunology and Medical Genetics The
Ohio State University Medical Center,
Columbus, Ohio, USA, "Causes and
consequences of microRNA Dysregulation in cancer"
- Nicholas Haining, Assistant
Professor of Pediatrics, Department of Pediatric Oncology
Dana-Farber Cancer Institute, Harvard Medical
School, Boston, MA, USA,
"Gene-expression based high-throughput screening"
- Anna E. Lokshin, PhD, Hillman
Cancer Institute, Luminex Core Facility, University of Pittsburgh, USA, "Urine as a source of cancer
biomarkers"
The afternoon session will feature a special xTAG RVP Fast
Workshop on current and future trends in respiratory viral
testing.
For detailed information regarding the Planet xMAP Europe 2010 symposium and agenda, or to
register online, please visit http://www.planetxmap.com.
About Luminex Corporation
Luminex Corporation develops, manufactures and markets
proprietary biological testing technologies with applications
throughout the diagnostic and life sciences industries. The
Company's xMAP® multiplex solutions include an open-architecture,
multi-analyte technology platform that delivers fast, accurate and
cost-effective bioassay results to markets as diverse as
pharmaceutical drug discovery, clinical diagnostics and biomedical
research, including the genomics and proteomics markets. The
Company's xMAP technology is sold worldwide and is already in use
in leading clinical laboratories as well as major pharmaceutical,
diagnostic and biotechnology companies. Further information on
Luminex Corporation or xMAP can be obtained at
www.luminexcorp.com.
Luminex Corporate
Contact:
|
|
Harriss T. Currie
|
|
Vice President, Finance and
Chief Financial Officer
|
|
512.219.8020
|
|
|
|
Matthew Scalo
|
|
Sr. Director Investor
Relations
|
|
512.219.8020
|
|
mscalo@luminexcorp.com
|
|
|
|
Luminex Media
Contact:
|
|
Aaron De Lucia
|
|
512-241-2249
|
|
aaron.delucia@porternovelli.com
|
|
|
SOURCE Luminex Corp.
Copyright . 13 PR Newswire